Hidradenitis Suppurativa (HS)
Log out
to your PfizerFlex
Patient Support Program
for ABRILADA
Hidradenitis Suppurativa (HS)
Hidradenitis suppurativa (HS) is a fairly common chronic skin condition that leads to tender, expanding, inflamed lumps under the skin. HS affects an estimated 1 million Canadians (almost 4 out of every 100 adults) and has been found to more commonly develop in women than men.
ABRILADA is used to treat adults and adolescents (12–17 years old, weighing ≥30 kg) with moderate to severe hidradenitis suppurativa (HS) who did not respond to antibiotics.
Your immune system works to protect your body from bacteria, viruses, and other foreign agents. In HS, the immune system mistakenly recognizes the body as foreign and attacks healthy body cells.
When you have HS, your immune system overproduces a substance called TNF-alpha (which stands for tumour necrosis factor alpha). The extra TNF-alpha can attack normal healthy body tissues and cause inflammation.
The way ABRILADA works is by binding to TNF-alpha and decreasing the inflammation process of HS. However, ABRILADA can also lower the body’s ability to fight infections, and taking it can make you prone to getting infections, or make any infection worse.
ABRILADA is administered by injection under the skin, also called a subcutaneous injection.
ABRILADA ®, Pfizer Inc., owner/ Pfizer Canada ULC, Licensee
PFIZERFLEX TM, Pfizer Inc., owner/ Pfizer Canada ULC, Licensee
© 2024 Pfizer Canada ULC, Kirkland, Quebec H9J 2M5
PP-ABD-CAN-0037-EN
